![conference banner](/images/conference-banner.jpeg)
Abstract
The treatment of brain diseases has been a major challenge since a long time. Although there are several potent drugs, which are highly therapeutic yet their efficiency is marred due to the presence of the Blood Brain Barrier (BBB). The BBB, which is present at the capillary level regulates and monitors the entry of all small and large molecules entering into the brain. Although this barrier is of immense importance to the brain in terms of safety, it becomes a hindrance when it comes to therapy because the drug molecules are unable to reach the brain. Various biomaterial-based strategies are being developed to overcome the BBB and deliver the drug into the brain. These include polymeric nanoparticles, liposomes, solid-lipid nanoparticles (SLNPs), nanogels, implants, etc. This review provides an overview on CNS disorders, BBB, and various delivery strategies available for biologists engaged in translational neuroscience, to target CNS.
Keywords: Blood-brain barrier (BBB), CNS drug delivery, drug transport, targeting.
Central Nervous System Agents in Medicinal Chemistry
Title:Targeted Drug Delivery to Central Nervous System (CNS) for the Treatment of Neurodegenerative Disorders: Trends and Advances
Volume: 14 Issue: 1
Author(s): Kritika Goyal, Veena Koul, Yashveer Singh and Akshay Anand
Affiliation:
Keywords: Blood-brain barrier (BBB), CNS drug delivery, drug transport, targeting.
Abstract: The treatment of brain diseases has been a major challenge since a long time. Although there are several potent drugs, which are highly therapeutic yet their efficiency is marred due to the presence of the Blood Brain Barrier (BBB). The BBB, which is present at the capillary level regulates and monitors the entry of all small and large molecules entering into the brain. Although this barrier is of immense importance to the brain in terms of safety, it becomes a hindrance when it comes to therapy because the drug molecules are unable to reach the brain. Various biomaterial-based strategies are being developed to overcome the BBB and deliver the drug into the brain. These include polymeric nanoparticles, liposomes, solid-lipid nanoparticles (SLNPs), nanogels, implants, etc. This review provides an overview on CNS disorders, BBB, and various delivery strategies available for biologists engaged in translational neuroscience, to target CNS.
Export Options
About this article
Cite this article as:
Goyal Kritika, Koul Veena, Singh Yashveer and Anand Akshay, Targeted Drug Delivery to Central Nervous System (CNS) for the Treatment of Neurodegenerative Disorders: Trends and Advances, Central Nervous System Agents in Medicinal Chemistry 2014; 14 (1) . https://dx.doi.org/10.2174/1871524914666141030145948
DOI https://dx.doi.org/10.2174/1871524914666141030145948 |
Print ISSN 1871-5249 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6166 |
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Acid-Sensing Ion Channels Structural Aspects, Pathophysiological Importance and Experimental Mutational Data Available Across Various Species to Target Human ASIC1
Current Drug Targets Emerging Role of Interleukins for the Assessment and Treatment of Liver Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Recent Insights into COVID-19 in Children and Clinical Recommendations
Current Pediatric Reviews Improving Brain Drug Targeting Through Exploitation of The Nose-to- Brain Route: A Physiological and Pharmacokinetic Perspective
Current Drug Delivery “What Is And What Should Never Be”<sup>#</sup>: Use and Misuse of HPV Testing in Cervical Cancer Prevention Strategies
Current Women`s Health Reviews Understanding the Design Principles of Living Systems at the Nanoscale
Current Nanoscience Dimebon Attenuates the Aβ-Induced Mitochondrial Permeabilization
Current Alzheimer Research Statins and Solid Organ Transplantation
Current Pharmaceutical Design Novel and Emerging Drugs for Systemic Lupus Erythematosus: Mechanism of Action and Therapeutic Activity
Current Medicinal Chemistry Estrogen Receptor Polymorphisms: Significance to Human Physiology, Disease and Therapy
Recent Patents on DNA & Gene Sequences Suicidal emperipolesis: a process leading to cell-in-cell structures, T cell clearance and immune homeostasis.
Current Molecular Medicine Sympathetic Nervous System Dysfunction in Multiple Sclerosis, Linking Neurodegeneration to a Reduced Response to Therapy
Current Pharmaceutical Design Mitochondrial Toxicity in HAART: An Overview of In Vitro Evidence
Current Pharmaceutical Design The Association of ACT -17 A/T Polymorphism with Alzheimer’s Disease: A Meta-Analysis
Current Alzheimer Research Antimicrobial Precious-Metal Nanoparticles and their Use in Novel Materials
Recent Patents on Food, Nutrition & Agriculture Spinal Muscular Atrophy: More than a Disease of Motor Neurons?
Current Molecular Medicine Development of Energy-based Pharmacophore Model and Stepwise Virtual Screening of LRRK2 Inhibitors Through Molecular Dynamics and Mechanics
Letters in Drug Design & Discovery In Vitro and In Vivo Models of Multiple Sclerosis
CNS & Neurological Disorders - Drug Targets Oxidative Stress and Decreased Mitochondrial Superoxide Dismutase 2 and Peroxiredoxins 1 and 4 Based Mechanism of Concurrent Activation of AMPK and mTOR in Alzheimer’s Disease
Current Alzheimer Research Viral Myocarditis and Dilated Cardiomyopathy: Etiology and Pathogenesis
Current Pharmaceutical Design